LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: First case report of tumor lysis syndrome and acute renal failure after selinexor use in multiple myeloma.

    Castellon, Chrystina / Onkarappa Mangala, Yashvin / Perez Rodriguez, Audrik / Chaquette, Raymond / Meleveedu, Kapil S

    Leukemia & lymphoma

    2021  Volume 62, Issue 14, Page(s) 3536–3539

    MeSH term(s) Acute Kidney Injury/chemically induced ; Acute Kidney Injury/diagnosis ; Humans ; Hydrazines/adverse effects ; Multiple Myeloma/complications ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Triazoles ; Tumor Lysis Syndrome/diagnosis ; Tumor Lysis Syndrome/etiology
    Chemical Substances Hydrazines ; Triazoles ; selinexor (31TZ62FO8F)
    Language English
    Publishing date 2021-08-09
    Publishing country United States
    Document type Case Reports ; Letter
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2021.1961230
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia.

    Meleveedu, Kapil S / Chen, Dong / Nadiminti, Kalyan / Sidiqi, Hasib / Khan, Shakila / Alkhateeb, Hassan / Shah, Mithun V / Patnaik, Mrinal / Hogan, William J / Begna, Kebede / Litzow, Mark

    Leukemia & lymphoma

    2019  Volume 62, Issue 3, Page(s) 764–767

    MeSH term(s) B7-H1 Antigen/genetics ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/genetics ; Programmed Cell Death 1 Receptor/genetics
    Chemical Substances B7-H1 Antigen ; Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2019-10-12
    Publishing country United States
    Document type Letter
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2019.1675880
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Tocilizumab for severe COVID-19 related illness - A community academic medical center experience.

    Meleveedu, Kapil S / Miskovsky, John / Meharg, Joseph / Abdelrahman, Abd / Tandon, Richa / Moody, Ashley E / Dasilva, Priscilla / Masse, Gabrielle / LaPorte, Jason / Saied Calvino, Abdul / Allen, Greg / El-Bizri, Rabih / Roberts, Todd / Armenio, Vincent / Katz, Steven C

    Cytokine: X

    2020  Volume 2, Issue 4, Page(s) 100035

    Abstract: The SARS-CoV-2 virus responsible for the COVID-19 pandemic can result in severe or fatal disease in a subset of infected patients. While the pathogenesis of severe COVID-19 disease has yet to be fully elucidated, an overexuberant and harmful immune ... ...

    Abstract The SARS-CoV-2 virus responsible for the COVID-19 pandemic can result in severe or fatal disease in a subset of infected patients. While the pathogenesis of severe COVID-19 disease has yet to be fully elucidated, an overexuberant and harmful immune response to the SARS-CoV-2 virus may be a pivotal aspect of critical illness in this patient population. The inflammatory cytokine, IL-6, has been found to be consistently elevated in severely ill COVID-19 patients, prompting speculation that IL-6 is an important driver of the pathologic process. The inappropriately elevated levels of inflammatory cytokines in COVID-19 patients is similar to cytokine release syndrome (CRS) observed in cell therapy patients. We sought to describe outcomes in a series of severely ill patients with COVID-19 CRS following treatment with anti-IL-6/IL-6-Receptor (anti-IL-6/IL-6-R) therapy, including tocilizumab or siltuximab. At our academic community medical center, we formed a multi-disciplinary committee for selecting severely ill COVID-19 patients for therapy with anti-IL-6 or IL-6-R agents. Key selection criteria included evidence of hyperinflammation, most notably elevated levels of C-reactive protein (CRP) and ferritin, and an increasing oxygen requirement. By the data cutoff point, we treated 31 patients with anti-IL-6/IL-6-R agents including 12 who had already been intubated. Overall, 27 (87%) patients are alive and 24 (77%) have been discharged from the hospital. Clinical responses to anti-IL-6/IL-6-R therapy were accompanied by significant decreases in temperature, oxygen requirement, CRP, IL-6, and IL-10 levels. Based on these data, we believe anti-IL-6/IL-6-R therapy can be effective in managing early CRS related to COVID-19 disease. Further study of anti-IL-6/IL-6-R therapy alone and in combination with other classes of therapeutics is warranted and trials are underway.
    Keywords covid19
    Language English
    Publishing date 2020-09-02
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2590-1532
    ISSN (online) 2590-1532
    DOI 10.1016/j.cytox.2020.100035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma.

    Nadiminti, Kalyan / Sidiqi, M Hasib / Meleveedu, Kapil / Alkhateeb, Hassan B / Hogan, William J / Litzow, Mark / Patnaik, Mrinal / Kumar, Shaji / Gertz, Morie / Chen, Dong / Shah, Mithun Vinod

    Blood cancer journal

    2021  Volume 11, Issue 3, Page(s) 63

    MeSH term(s) Aged ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Leukemia, Myeloid/etiology ; Leukemia, Myeloid/therapy ; Male ; Middle Aged ; Multiple Myeloma/therapy ; Myelodysplastic Syndromes/etiology ; Myelodysplastic Syndromes/therapy ; Survival Analysis ; Transplantation, Autologous/adverse effects
    Language English
    Publishing date 2021-03-19
    Publishing country United States
    Document type Letter
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-021-00454-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function.

    Sidiqi, M Hasib / Nadiminti, Kalyan / Al Saleh, Abdullah S / Meleveedu, Kapil / Buadi, Francis K / Dispenzieri, Angela / Warsame, Rahma / Lacy, Martha Q / Dingli, David / Leung, Nelson / Gonsalves, Wilson I / Kapoor, Prashant / Kourelis, Taxiarchis V / Hogan, William J / Kumar, Shaji K / Gertz, Morie A

    Bone marrow transplantation

    2019  Volume 54, Issue 11, Page(s) 1775–1779

    Abstract: We retrospectively reviewed the impact of impaired renal function (eGFR < 45 ml/min/SA) on post-transplant outcomes in patients receiving ASCT for AL amyloidosis. Patients were grouped into two cohorts, those with normal renal function (NRF) eGFR ≥ 45 ml/ ...

    Abstract We retrospectively reviewed the impact of impaired renal function (eGFR < 45 ml/min/SA) on post-transplant outcomes in patients receiving ASCT for AL amyloidosis. Patients were grouped into two cohorts, those with normal renal function (NRF) eGFR ≥ 45 ml/min (n = 568) and those with impaired renal function (IRF) eGFR < 45 ml/min (n = 87). Patients with IRF had higher renal stage (>Stage 1: 100% IRF vs 37% NRF, p < 0.0001) and the majority received conditioning with melphalan <200 mg/m
    MeSH term(s) Adult ; Aged ; Autografts ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunoglobulin Light-chain Amyloidosis/mortality ; Immunoglobulin Light-chain Amyloidosis/therapy ; Male ; Melphalan/administration & dosage ; Middle Aged ; Renal Dialysis ; Renal Insufficiency/mortality ; Renal Insufficiency/therapy ; Survival Rate ; Transplantation Conditioning
    Chemical Substances Melphalan (Q41OR9510P)
    Language English
    Publishing date 2019-04-08
    Publishing country England
    Document type Clinical Trial ; Journal Article
    ZDB-ID 632854-4
    ISSN 1476-5365 ; 0268-3369 ; 0951-3078
    ISSN (online) 1476-5365
    ISSN 0268-3369 ; 0951-3078
    DOI 10.1038/s41409-019-0524-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Tocilizumab for severe COVID-19 related illness – A community academic medical center experience

    Meleveedu, Kapil S / Miskovsky, John / Meharg, Joseph / Abdelrahman, Abd / Tandon, Richa / Moody, Ashley E. / Dasilva, Priscilla / Masse, Gabrielle / LaPorte, Jason / Saied Calvino, Abdul / Allen, Greg / El-Bizri, Rabih / Roberts, Todd / Armenio, Vincent / Katz, Steven C.

    Cytokine: X

    2020  Volume 2, Issue 4, Page(s) 100035

    Keywords covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ISSN 2590-1532
    DOI 10.1016/j.cytox.2020.100035
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Tocilizumab for severe COVID-19 related illness - A community academic medical center experience

    Meleveedu, Kapil S / Miskovsky, John / Meharg, Joseph / Abdelrahman, Abd / Tandon, Richa / Moody, Ashley E / Dasilva, Priscilla / Masse, Gabrielle / LaPorte, Jason / Saied Calvino, Abdul / Allen, Greg / El-Bizri, Rabih / Roberts, Todd / Armenio, Vincent / Katz, Steven C

    Cytokine X

    Abstract: The SARS-CoV-2 virus responsible for the COVID-19 pandemic can result in severe or fatal disease in a subset of infected patients. While the pathogenesis of severe COVID-19 disease has yet to be fully elucidated, an overexuberant and harmful immune ... ...

    Abstract The SARS-CoV-2 virus responsible for the COVID-19 pandemic can result in severe or fatal disease in a subset of infected patients. While the pathogenesis of severe COVID-19 disease has yet to be fully elucidated, an overexuberant and harmful immune response to the SARS-CoV-2 virus may be a pivotal aspect of critical illness in this patient population. The inflammatory cytokine, IL-6, has been found to be consistently elevated in severely ill COVID-19 patients, prompting speculation that IL-6 is an important driver of the pathologic process. The inappropriately elevated levels of inflammatory cytokines in COVID-19 patients is similar to cytokine release syndrome (CRS) observed in cell therapy patients. We sought to describe outcomes in a series of severely ill patients with COVID-19 CRS following treatment with anti-IL-6/IL-6-Receptor (anti-IL-6/IL-6-R) therapy, including tocilizumab or siltuximab. At our academic community medical center, we formed a multi-disciplinary committee for selecting severely ill COVID-19 patients for therapy with anti-IL-6 or IL-6-R agents. Key selection criteria included evidence of hyperinflammation, most notably elevated levels of C-reactive protein (CRP) and ferritin, and an increasing oxygen requirement. By the data cutoff point, we treated 31 patients with anti-IL-6/IL-6-R agents including 12 who had already been intubated. Overall, 27 (87%) patients are alive and 24 (77%) have been discharged from the hospital. Clinical responses to anti-IL-6/IL-6-R therapy were accompanied by significant decreases in temperature, oxygen requirement, CRP, IL-6, and IL-10 levels. Based on these data, we believe anti-IL-6/IL-6-R therapy can be effective in managing early CRS related to COVID-19 disease. Further study of anti-IL-6/IL-6-R therapy alone and in combination with other classes of therapeutics is warranted and trials are underway.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #739799
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top